Clinical Research in the Northwest

Why bother to participate in clinical trials and observational studies? Because, without participation we will never have new treatments for Huntington's.

Clinical Trials

Omeros New PDE-10 Inhibitor Drug
(NOW enrolling)
This Phase 2 safety and tolerability clinical trial is now open for enrollment at Evergreen Neuroscience Center. Three different doses of the drug will be tested and compared with placebo.

There are 9 patient visits in total; the first is for screening and the final two are follow-up after the drug trial is completed.

Criteria include: Age between 18 and 65, and not currently on an investigational drug. You may be on an antipsychotic drug, but the dosage must be the same for at least 60 days.

Evergreen Neuroscience Center 
Dr. Pinky Agarwal,
Primary Investigator

Julissa Leon
Research Coordinator
12039 128th St., Suite 300,
Kirkland, WA 98034
Phone: 425.899.5370
Fax: 425.899.3147
Email: jaleon@evergreenhealth.com
 
First-HD
(NOW Enrolling)

FFirst-HD, a Phase 3 clinical trial testing a long-acting form of tetrabenazine (Xenazine) is open for enrollment at Evergreen Neuroscience Center and the University of Washington It is hoped that the long acting preparation will have fewer side effects and be more convenient for patients to take.

Each site is looking for at least 6 participants who have moderate or severe chorea who have never been on tetrabenazine (Xenazine) or have not used Xenazine for at least 6 months and are not presently on an antipsychotic drug (like olanzapine or risperidone or others).

Study length is 4 months, with 8 in-person visits and 7 by telephone. There is 50/50 chance of getting drug or placebo. Subsequently, participants who are eligible may continue into another study where all will receive the active drug. We need more participants now. br>
Transportation expenses will be reimbursed.

Evergreen Neuroscience Center 
Dr. Pinky Agarwal,
Primary Investigator

Julissa Leon
Research Coordinator
12039 128th St., Suite 300,
Kirkland, WA 98034
Phone: 425.899.5370
Fax: 425.899.3147
Email: jaleon@evergreenhealth.com

University of Washington Department of Neurology
Dr. Ali Samii, MD,
Primary Investigator

Emily P. Freney,
Research Coordinator
 
Phone: 206.543.3647
Fax: 206.685.8100
Email: efreney@uw.edu 
CREST-E



READ MORE
For symptomatic HD individuals: This is a Phase 3 clinical trial that is testing whether high dose creatine can slow disease progression for those diagnosed with HD. Creatine is a nutritional supplement that has shown benefit in some HD mouse models. Potential benefit for individuals with HD has been suggested in earlier Phase 2 study (for safety and dosage testing) performed in Boston where decreased brain atrophy was shown for those individuals who took high dose creatine. This is a 3-year clinical trial. For full description visit www.hdtrials.org  or www.clinicaltrials.gov


Booth Gardner Parkinson's Care Center 
Dr. Pinky Agarwal,
Primary Investigator

Julissa Leon
Research Coordinator
12039 128th St., Suite 300,
Kirkland, WA 98034
Phone: 425.899.5370
Fax: 425.899.3147
Email: jaleon@evergreenhealth.com



Observational and Clinical Research Studies

Muscle and Brain Biomarker Study for HD
(now enrolling)
This study will be conducted at the University of Washington and will involve only 2 visits separated by about 1 week. Each participant will receive an MRI scan of a leg muscle and of brain. The purpose of the study is to improve our ability to measure mitochondrial energy levels. It is hoped that these measures can be used as a biomarker that will speed clinical trials of new drugs.

Investigators are looking for 15 participants who have tested positive for the HD gene, but have no or very early symptoms and 10 gene negative individuals who can serve as controls.  
 
Dr. Kevin Conley and
Dr. Elizabeth Aylward
Principle Investigators
 
Contact Dr. Sharon Jubrias
206-543-3763
for enrollment information
Predict HD
(now enrolling)


READ MORE
The purpose of this study is to learn more about the diagnosis and progress of Huntington's Disease (HD). We are asking people over the age of 18 years, who have the gene for HD, but have not had an abnormal neurological examination, to take part in this study. We are also asking people who were at risk for HD but do not carry the gene (gene negative) to participate, for purposes of comparison. We will use paper-and-pencil tests, computer test, brain scans (MRI), blood and urine tests, and examinations by a doctor, to learn what happens as people move from health to HD.

University of Washington Department of Neurology
Dr. Ali Samii, MD,
Primary Investigator

Emily P. Freney,
Research Coordinator
 
Phone: 206-543-3647
Fax: 206-685-8100
Email: efreney@uw.edu 
ENROLL-HD
(now enrolling)

previously COHORT

READ MORE
Enroll-HD study is a new international study that involves North America, Europe, South America and parts of Asia. Data from those of you who have already contributed to COHORT (with your permission) will added to Enroll-HD.

This study is an active collaboration of HD patients, individuals born at risk for HD (regardless of whether they have been tested genetically), and their families. It requires about a half day visit once a year. This study is vital to the more rapid development of treatments for HD therapeutics and completion of clinical trials. Visit EnrollHD.org for more information and updates.

Transportation reimbursement available.  

Booth Gardner Parkinson’s Care Center (Evergreen Neuroscience Center)
Dr. Pinky Agarwal,
Primary Investigator

Marsha Merrick,
Coordinator
12039 NE 128th Street, Suite 300
Kirkland, WA 98034
Phone: 425-899-3115
Fax: 425-899-3147
Email: mgmerrick@
evergreenhealthcare.org
 

University of Washington Department of Neurology
Dr. Ali Samii,
Primary Investigator

Emily P. Freney,
Research Coordinator
Phone: 206.543.3647
Fax: 206.685.8100
Email: efreney@uw.edu  



Previous Clinical Research Results

Reach2HD
(enrollment closed)

Reach2HD, a Phase 2 clinical trial at Evergreen Neuroscience Center is now completed. Safety was demonstrated and results suggested a possible cognitive improvement: http://pranabio.com/news/prana-announces-successful-phase-2-results-huntington-disease-trial/#.UynpWF6ayfY. The company plans to move to a Phase 3 trial. Though the Northwest had a very short time period for enrolling participants, we had 6 accepted into the trial. Thank you to all participants, and to Evergreen for their clinical trial efforts for Huntington's disease.
HART-ACR16
(closed)
This phase 2 trial has been completed and gave a positive signal of benefit for motor symptoms. A new trial is planned for 2014.
Dimebon Phase 3
(closed)
Unfortunately this trial showed no benefit in Huntington’s or Alzheimer’s disease.



HDSA
NW Chapter Home
Helpline: 888-264-4372
Contact us:
- social worker
- join mailing list
- volunteer

READ MORE